Drug Profile
RWJ 67657
Alternative Names: RWJ-67657Latest Information Update: 27 May 2010
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Antirheumatics; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections; Rheumatoid arthritis
Most Recent Events
- 16 Nov 2004 A preclinical study has been added to the Rheumatic Disease pharmacodynamics section
- 09 Aug 2004 Data presented at the 15th International AIDS Conference (IAC-2004) have been added to the Viral Infections antimicrobial activity section
- 24 Jun 2004 Data presented at the Annual European Congress of Rheumatology (EULAR-2004) have been added to the Rheumatic Disease pharmacodynamics section